A bipartisan coalition of lawmakers from the House and Senate sent a letter to the Justice Department on Friday, requesting a policy change allowing researchers to access marijuana from state-legal dispensaries to improve studies on the plantâ€™s benefits and risks.
The letter, led by Rep. Harley Rouda (D-CA) and Sen. Brian Schatz (D-HI), cites feedback from federal health agencies, which have said that existing restrictions on cannabis have inhibited research. One problem in particular is that thereâ€™s only one federally authorized manufacturer of research-grade marijuana.
While the Drug Enforcement Administration (DEA) said that it is in the process of approving additional manufacturers, itâ€™s been more than three years since they first announced that applications for more growers would be accepted and, more recently, the agency said it would have to develop alternative rules to approve proposalsÂ that have been submitted.
â€śAt the same time, the status quo does not address a barrier to research raised by both [the National Institutes of Health] and [the Food and Drug Administration],â€ť the lawmakers wrote in the new letter. That barrier is a ban on researchers being able to obtain marijuana from dispensaries.
â€śBoth agencies recommended that researchers should be able to obtain cannabis from state-legal sources,â€ť the letter states.
Today, @SenBrianSchatz and I sent a bipartisan letter to AG Barr, urging the DEA to amend current policies to improve research on cannabis.
Itâ€™s time to bring our drug research policies into the 21st century.https://t.co/bfpPUhUvQf
â€” Rep. Harley Rouda (@RepHarley) December 6, 2019
Further, the lawmakers said that there are â€śproblems in industry development of licensed drugs with data from products obtained from third-parties, such as the University of Mississippi.â€ť
â€śIn many states, cannabis law and regulations already provide for licensing of industrial manufacturing activities, and products are available for medical use in those states, but not for research leading to FDA licensure,â€ť they wrote.
â€śThere is a need for a greater diversity of cannabis products so that research on benefits and risks reflects the realities of what consumers and patients are using. NIH and FDA have strongly recommended streamlining the process for conducting research and product development activities with cannabis and other Schedule I substances, and that the DEA take action to assure that interpretations of processes and policies are universally applied in local DEA jurisdictions.â€ť
The lack of chemical diversity in the federal governmentâ€™s cannabis supply has been repeatedly pointed out. One study found that the research-grade cannabis is more similar to hemp than marijuana in commercial markets.
To resolve the research issues, the coalition made two recommendations: 1) to amend internal policy â€śso as to allow researchers with Schedule I licenses to obtain cannabis-derived products from state authorized dispensaries for research purposesâ€ť and 2) issue guidance clarifying that hemp researchers do not need a DEA license to obtain and study hemp because it was federally legalized under the 2018 Farm Bill.
The letter requests a response from DEA by December 20.
A total of 21 members of Congress signed the letter, including Sens. Kamala Harris (D-CA) and Cory Gardner (R-CO), along with Reps. Earl Blumenauer (D-OR), Barbara Lee (D-CA) Matt Gaetz (R-FL) and Joe Kennedy (D-MA).
â€śOur nationâ€™s cannabis research laws are archaic,â€ť Rouda said in a press release. â€śForty-seven states have legalized some form of cannabis consumptionâ€”we must ensure our federal agencies and other licensed institutions can comprehensively study the benefits and risks of cannabis products.â€ť
â€śI thank Senator Schatz, and my colleagues on both sides of the aisle, for joining me to make this common-sense request,â€ť he said. â€śItâ€™s time to bring our drug research policies into the 21st century.â€ť
Attorney General William Barr received a similar letter from lawmakers about the need to expand the number of federally authorized marijuana cultivators in April.
Read the lawmakersâ€™ full letter on expanding marijuana research below: